Press Release | Sun Dec 5, 2010 8:33am EST

Seattle Genetics and Millennium Report Positive Data From Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or

* Reuters is not responsible for the content in this press release.